• Company
• ‘Leclaza will be free as first-line Tx until reimbursement'
• by Kim, Jin-Gu Jul 11, 2023 05:41am

• Company
• 'Leclaza effective as 1st-line treatment in Koreans'
• by Kim, Jin-Gu Jul 11, 2023 05:41am

• Company
• Pricing negotiations for Spinraza's reimb begin in KOR
• by Eo, Yun-Ho Jul 11, 2023 05:41am

• Company
• Yuhan provides Leclaza with 6 million won per month for free
• by Kim, Jin-Gu Jul 11, 2023 05:40am

• Company
• Will the non-reimbursed Gavreto vanish in Korea?
• by Jung, Sae-Im Jul 10, 2023 05:21am

• Company
• 3 new asthma drugs resumed discussion on reimbursement
• by Eo, Yun-Ho Jul 10, 2023 05:21am

• Policy
• Gov’s halts price cut discussions on generics
• by Lee, Jeong-Hwan Jul 10, 2023 05:21am

• Company
• New AML drug Vyxeos can be prescribed at general hospitals
• by Eo, Yun-Ho Jul 10, 2023 05:21am

• Company
• Daiichi's sales rose & Astellas' sales fell
• by Jung, Sae-Im Jul 10, 2023 05:20am

• Company
• Boryung’s new drug Zepzelca lands in Big 5 hospitals in KOR
• by Eo, Yun-Ho Jul 7, 2023 05:43am